During the same time period, the proportion of adults 20 and older prescribed buprenorphine, one of three medications approved by the FDA to treat opioid use disorder, increased by 47 percent, said CDC researchers, who conducted the study based on IQVIA data from between 2015 and 2020.
The FDA has not yet approved buprenorphine for youth under 16, but waivers can be obtained to prescribe the medication off-label.
Many young people who could benefit from buprenorphine are not receiving it, according to the study research team, led by Andrew Terranella, MD, a medical epidemiologist in the CDC’s Division of Overdose Prevention.
“Efforts to expand access to MOUD for adolescents could include improving training in opioid use disorder treatment of pediatricians and encouraging all clinicians who care for adolescents and young adults to obtain waivers to prescribe buprenorphine for MOUD,” the article said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
